Search

Author/Creator Mehr, Keyvan Tadjalli

1. RNAdjuvant®, a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile. (4th November 2015)

Authors:
Heidenreich, Regina; Mehr, Keyvan Tadjalli; Noth, Janine; Koch, Sven; Hong, Henoch; Melber, Karl; Daehling, Angelika; Roos, Tilmann; Lutz, Johannes; Kowalczyk, Aleksandra; Baumhof, Patrick; Scheel, Birgit; Voss, Söhnke; Kallen, Karl-Josef; Fotin-Mleczek, Mariola; Gnad-Vogt, Ulrike
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Issue 10101 (23rd September 2017)

Authors:
Alberer, Martin; Gnad-Vogt, Ulrike; Hong, Henoch Sangjoon; Mehr, Keyvan Tadjalli; Backert, Linus; Finak, Greg; Gottardo, Raphael; Bica, Mihai Alexandru; Garofano, Aurelio; Koch, Sven Dominik; Fotin-Mleczek, Mariola; Hoerr, Ingmar; Clemens, Ralf; von Sonnenburg, Frank
Journal:
Lancet
Issue:
Volume 390:Issue 10101(2017)
Page Start:
1511
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search